PRTODAY / NewswireToday Free press release distribution service network

Written by / Agency / Source: The Scott Partnership

Check Ads Availability|e-mail Article


Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!

Biotage Unveils Unique Parallel Peptide Synthesizer with Automated Microwave Technology - Unique parallel peptide synthesizer with Automated Microwave Technology offers
Biotage Unveils Unique Parallel Peptide Synthesizer with Automated Microwave Technology

 

NewswireToday - /newswire/ - Uppsala, Sweden, 2010/02/18 - Unique parallel peptide synthesizer with Automated Microwave Technology offers "The Best of Both Worlds" for peptide chemists.

   
 
Your Banner Ad Here instead - Showing along with ALL Articles covering Pharma/BioTech/Nutrition Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


 

Biotage, a leading supplier of tools and technology for medicinal and analytical chemistry, today announced the eagerly awaited global launch of the Syro Wave; its new microwave and parallel peptide synthesizer. The Syro Wave is a result of the joint development project announced last year between Biotage and MultiSynTech. It combines the proven performance of the established MultiSynTech robotic synthesizer with Biotage microwave technology.

The Syro Wave peptide synthesis system is the only system on the market that offers both microwave and parallel peptide synthesis capabilities. To date peptide synthesis labs have been required to invest in both standalone parallel systems for productivity and cost efficiency, and standalone microwave systems for difficult or longer peptides. This results in increased demand on bench space, duplication of computer control systems, and multiple operating software platforms for chemists to learn and maintain. Biotage has addressed these shortcomings with the Syro Wave, containing both parallel and microwave technologies on the same platform.

The new Biotage Syro Wave increases productivity, yield and purity while cutting costs and saving time. "At Biotage the focus is on developing technology to speed up and simplify experimental procedures while simultaneously driving down operating costs. Whether the customer is a Pharma development group, a CRO focused on cost and productivity or an Academic researcher focused on unique sequences, the Syro Wave fits," noted Scott Carr, Vice President Commercial Operations, Biotage.

For further press information please contact: Eleanor Thouret, The Scott Partnership, 1 Whiteside, Station Road, Holmes Chapel, Cheshire CW4 8AA F: +44 1477 539540; E: biotage[.]scottpr.com.

About Biotage
Biotage (biotage.com) is a global technology based company, which provides tools for life science research. The company offers a broad range of solutions, knowledge and experience in the areas of analytical and medicinal chemistry. Customers include the world's top 30 pharmaceutical companies, the world's top 20 biotech companies, and leading academic institutes. The company is headquartered in Uppsala, Sweden and has subsidiaries in the United States, United Kingdom and Japan. Biotage has 270 employees and had sales of SEK 385,3m in 2008. Biotage is listed on the NASDAQ OMX Nordic Stock Exchange.

 
 
Your Banner Ad Here instead - Showing along with ALL Articles covering Pharma/BioTech/Nutrition Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


 

Written by / Agency / Source: The Scott Partnership

 
 

Availability: All Regions (Including Int'l)

 

Traffic Booster: [/] Quick Newswire Today Visibility Checker

 

Distribution / Indexing: [+]

 
 
# # #
 

 
  Your Banner Ad showing on ALL
Pharma/BioTech/Nutrition articles,
CATCH Visitors via Your Competitors Announcements!


Biotage Unveils Unique Parallel Peptide Synthesizer with Automated Microwave Technology

Company website links NOT available to basic submissions
It is OK to republish and/or LINK any newswire for any legitimate media purpose as long as you name Newswire Today and LINK as the source.
 
  Is this your article?
Activate ALL web links and social stream by Upgrading to Press Release PREMIUM Plan Now!

|
Publisher Contact: Eleanor Thouret 
+44 1477 539539 product_info[.]biotage.com
 
Newswire Today - PRZOOM / PRTODAY disclaims any content contained in this article. If you need/wish to contact the company who published the current release, you will need to contact them - NOT us. Issuers of articles are solely responsible for the accuracy of their content. Our complete disclaimer appears here.
IMPORTANT INFORMATION: Issuance, publication or distribution of this press release in certain jurisdictions could be subject to restrictions. The recipient of this press release is responsible for using this press release and the information herein in accordance with the applicable rules and regulations in the particular jurisdiction. This press release does not constitute an offer or an offering to acquire or subscribe for any The Scott Partnership securities in any jurisdiction including any other companies listed or named in this release.

Pharma/BioTech/Nutrition via RSSAdd NewswireToday - PRZOOM Headline News to FeedBurner
Find who RetweetFollow @NewswireTODAY



Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!


Read Latest Articles From The Scott Partnership / Company Profile


Read Pharma/BioTech/Nutrition Most Recent Related Newswires:

First Pulmonary Embolism Patients in Hong Kong Treated with the EKOS® System
Ipsen to Acquire Oncology Assets from Merrimack Pharmaceuticals
FDA Grants Genentech’s Cancer Immunotherapy Tecentriq® (Atezolizumab) Priority Review in Additional Type of Advanced Bladder Cancer
FDA Approves Genentech’s Lucentis® (Ranibizumab Injection) for Myopic Choroidal Neovascularization
Sugar Element of Keratan Sulfate Halts the Progress of Emphysema Finds RIKEN
Exelixis and Ipsen Amend Exclusive Licensing Agreement for the Commercialization and Development of Cabozantinib to Include Canada
FDA Extends Review of Application for OCREVUS™ (Ocrelizumab)
MDxHealth Announces AceCGT Life Science Limited as the Exclusive Distributor for SelectMDx in Hong Kong and Macao China
Pulse Certified As A Level Four Multichannel Content Agency by Veeva Systems
BD Launches Advanced Prefillable Syringe for Higher Volume Injection of Biologics
Sartorius Announces Expansion of Sartorius Stedim Cellca
Frost & Sullivan Commends Nemaura for Developing Superior Transdermal Drug Delivery Technology Platforms, the Memspatch and Micropatch
Greenphire Sponsors Second Annual Clinical Trial Agreements, Investigator Payments and Fair Market Value Meeting
BD Integrating Technology, Expertise and Services to Provide Comprehensive Medication Management
Genentech’s Gazyva Helped People with Previously Untreated Follicular Lymphoma Live Significantly Longer

Boost Your Social Network
& Crowdfunding Campaigns


LIFETIME SOCIAL MEDIA WALL
NewswireToday Celebrates 10 Years in Business


PREMIUM Members


Visit  BizJobs.com

Visit  Intrinsic Executive Search Ltd





 
  ©2017 Newswire Today — Limelon Advertising, Co.
Home | About | Advertise/Pricing | Contact | Investors | Privacy/TOS | Sitemap | FRANCAIS
newswire, PR free press releases distribution service magazines engine news alert newsroom press room breaking news public relations articles company news alerts newswiredistribution ezine bizentrepreneur biznewstoday digital business report market search pr firms agencies reports distri-bution today investor relation successful internet entrepreneurs newswire distribution prtoday.com freenewswiredistribution asianewstoday bizwiretoday USA pr UK today - NOT affiliated with PRNewswire as we declined their partnership offer in 2013
 
PRTODAY & NewswireTODAY are NOT affiliated with USA TODAY (usatoday.com)